Natco Pharma opened a rights issue: what it means for Natco Pharma stock

Published on 10/14/2026 at 00:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The offer gives two rights shares per 21 held at INR 750 each. For Natco Pharma stock, 17,058,082 shares are offered through October 22, 2026.

Capital raise and operating figures

Natco Pharma's rights issue opened on October 12, 2026, raising up to INR 12.79 billion.
First-quarter fiscal 2027 revenue reached INR 7.94 billion and profit after tax was INR 2.07 billion.
Natco Pharma stock was last quoted at INR 789.15 on NSE on October 13, 2026.

Natco, INE987B01026, Illustration mit AI erstellt.

Natco Pharma opened a rights issue on October 12, 2026, offering up to INR 12.79 billion at INR 750 per share. Whalesbook reports that the offer covers 17,058,082 equity shares, with two rights shares for every 21 held. The capital raise gives Natco a defined funding route for debt reduction, research and development, and inorganic growth.

Three dated corporate developments

On August 14, 2026, Natco reported first-quarter fiscal 2027 revenue of INR 7.94 billion and profit after tax of INR 2.07 billion, according to Natco Pharma. On September 29, 2026, the company increased its proposed eGenesis investment to USD 16.70 million from USD 14.00 million, as Business Standard reported. On October 12, 2026, the rights issue opened at INR 750 per share, according to Whalesbook.

What does the raise change?

The offer allocates INR 8.11 billion toward debt repayment and INR 1.10 billion toward research and development, with further funds available for inorganic initiatives, Whalesbook reported. The offer is therefore both a balance-sheet measure and a source of capital for future portfolio expansion.

Key dates for the offer

Rights entitlements can be renounced through October 16, 2026, and the issue closes on October 22, 2026, according to Whalesbook. The issue also provides two rights shares for every 21 existing shares held on the October 1, 2026 record date, making the entitlement ratio central to the near-term shareholder decision.

Natco stock valuation context

Natco Pharma was last quoted at INR 789.15 on NSE on October 13, 2026 at 3:58 p.m. IST. The same dated market context put its market capitalization at INR 141.3 billion and its 52-week range at INR 787.20 to INR 1,226.80. These figures place the last quote 35.67 percent below the 52-week high, while the INR 750 rights price stands below the last quoted market level.